+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Basal Cell Carcinoma Treatment Market by Type (Drug Therapy, Radiation Therapy, Surgery), Route of Administration (Oral, Parenteral), Clinical Variant, End-Users - Forecast 2024-2030- Product Image
Global Basal Cell Carcinoma Treatment Market by Type (Drug Therapy, Radiation Therapy, Surgery), Route of Administration (Oral, Parenteral), Clinical Variant, End-Users - Forecast 2024-2030- Product Image
Sale

Global Basal Cell Carcinoma Treatment Market by Type (Drug Therapy, Radiation Therapy, Surgery), Route of Administration (Oral, Parenteral), Clinical Variant, End-Users - Forecast 2024-2030

  • PDF Icon

    Report

  • 193 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 5924690
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Basal Cell Carcinoma Treatment Market grew from USD 6.47 billion in 2023 to USD 6.94 billion in 2024. It is expected to continue growing at a CAGR of 7.67%, reaching USD 10.87 billion by 2030.

This cancer grows slowly and majorly affects areas of the skin that experience frequent sun exposure, such as the face, ears, and scalp. Treatments vary depending on the size, location, and severity of the tumor and include surgical methods such as excision and micrographically oriented histographic (Mohs) surgery, topical medications, radiation therapy, and, in advanced cases, targeted drug therapies. The rising number of skin cancer cases globally, particularly basal cell carcinomas, driven by increased ultraviolet (UV) exposure and aging populations, significantly propels the need for quick and effective treatments. Growing awareness about skin cancer symptoms, risks, and preventive measures, largely due to public health campaigns and increased media coverage, has led more individuals to seek early diagnosis and treatment for BCC. However, certain BSS treatments, such as Mohs surgery, require high levels of expertise and precision, and the lack of skilled professionals poses hurdles to the adoption of BCC treatments. Moreover, the possibility of side effects and inaccurate and ineffective treatment can dissuade patients from seeking BCC treatments. Continued research by key players and research institutions into the genetic and molecular mechanisms underlying basal cell carcinomas opens opportunities for the development of more targeted, personalized therapies that could improve treatment efficacy and reduce side effects. Expanding telemedicine services and integrating artificial intelligence for better diagnostic tools and treatment planning can make expert care more accessible, especially in underserved areas.

Regional Insights

In the Americas region, particularly the United States and Canada, basal cell carcinoma treatment is a highly advanced market driven by a robust healthcare infrastructure and significant investments in cancer research. Consumers in these regions benefit from early screening programs, which contribute to high awareness levels and early diagnosis. Patients prefer innovative treatments such as targeted therapies and advanced non-invasive technologies. Insurance coverage hugely impacts customer purchasing behavior, with most opting for treatments approved by health authorities. In the European Union, healthcare systems provide extensive coverage, influencing treatment accessibility and consumer purchasing decisions. There is a strong emphasis on cost-efficiency and evidence-based treatments. Recent EU-wide initiatives have aimed to harmonize cancer treatment protocols, increasing the accessibility of high-quality treatment options. Stringent regulations pertaining to the approval, safety, and efficacy of BCC treatments create a standardized framework and lead to the development of highly advanced and safe therapies. The APAC region presents an evolving landscape for the BCC treatment market, owing to growing awareness about skin cancers and government support for extending access to healthcare solutions. China, Japan, India, South Korea, Singapore, and Australia Japan offer significant investments in oncology research and healthcare infrastructure, emphasizing developing cost-effective treatment solutions. Digital health initiatives and the proliferation of telemedicine have played a key role in improving access to BCC treatment.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Basal Cell Carcinoma Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Prevalence of basal cell carcinoma worldwide
  • Growing awareness regarding early diagnosis and treatment of skin cancer globally

Market Restraints

  • High cost of basal cell carcinoma treatment

Market Opportunities

  • Advancements and improvements in BCC treatment
  • Emerging trend of telemedicine and teledermatology

Market Challenges

  • Concerns associated with stringent regulatory approval

Market Segmentation Analysis

  • Treatment Type: High effectiveness of drug therapies and surgery interventions in escalating the BCC completely
  • Route of Administration: Rapid effect provided by parenteral administration leading to its preference for managing severe BCC cases
  • Clinical Variant: Focused efforts to improve and provide advanced treatments for sclerosing and superficial spreading BCC to manage its aggressive nature
  • End-Users: Government support for expanding and modernizing hospital and clinic facilities

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Basal Cell Carcinoma Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Basal Cell Carcinoma Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Elekta Unveils Evo, a Groundbreaking Adaptive CT-Linac for Enhanced Cancer Treatment

Elekta, a global company in precision radiation therapy solutions, unveiled its Evo CT-linac, offline and online adaptive radiation therapy, enhancing the precision of image-guided treatments. This state-of-the-art system combines high-definition AI-assisted imaging with versatile radiation therapy modalities, catering to individualized patient care.

Medicus Pharma Ltd. Advances Basal Cell Carcinoma Treatment Through Strategic Acquisitions and Enhanced Regulatory Strategies

Medicus Pharma Ltd., a biotech holding company, made significant strides in advancing therapies for basal cell carcinoma (BCC), following its acquisition of SkinJect, Inc. SkinJect, a Medicus subsidiary, holds an exclusive license for a revolutionary Dissolvable Microneedle Array drug delivery system. Over the past six months, Medicus Pharma Ltd. has expedited the FDA regulatory approval process for the SkinJect transdermal patch designed to treat BCC.

Innovative Advances in Non-Invasive Basal Cell Carcinoma Treatment by Medicus Pharma Ltd., Update on Regulatory Development and Clinical Studies

Medicus Pharma Ltd. has received feedback from the U.S. Food and Drug Administration (FDA) regarding their new treatment method for basal cell carcinoma (BCC), which involves the use of micro-array needles containing doxorubicin (D-MNA). The company planned to boost clinical trials as a significant step toward establishing a ground-breaking, non-invasive treatment option for BCC.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Basal Cell Carcinoma Treatment Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Basal Cell Carcinoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Almirall, LLC, Amgen Inc., Bausch Health Companies Inc., Biofrontera AG, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Galderma S.A., Glenmark Pharmaceuticals Limited, LEO Pharma A/S, Medicus Pharma Ltd., Medivir AB, OncoBeta GmbH, Perrigo Company PLC, Redx Pharma PLC, Regeneron Pharmaceuticals, Inc., Sanofi S.A., SkinCure Oncology, Sol-Gel Technologies Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Basal Cell Carcinoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type- Drug Therapy

  • Immunotherapy
  • Oral Medications
  • Targeted Therapy
  • Topical Medications
  • Radiation Therapy
  • Surgery

Route of Administration

  • Oral
  • Parenteral

Clinical Variant

  • Nodular Basal Cell Carcinoma
  • Pigmented Basal Cell Carcinoma
  • Sclerosing Basal Cell Carcinoma
  • Superficial Spreading Basal Cell Carcinoma

End-Users

  • Homecare
  • Hospitals & Clinics
  • Specialty Centres

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Illinois
  • Massachusetts
  • New Jersey
  • New York
  • North Carolina
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of basal cell carcinoma worldwide
5.1.1.2. Growing awareness regarding early diagnosis and treatment of skin cancer globally
5.1.2. Restraints
5.1.2.1. High cost of basal cell carcinoma treatment
5.1.3. Opportunities
5.1.3.1. Advancements and improvements in BCC treatment
5.1.3.2. Emerging trend of telemedicine and teledermatology
5.1.4. Challenges
5.1.4.1. Concerns associated with stringent regulatory approval
5.2. Market Segmentation Analysis
5.2.1. Treatment Type: High effectiveness of drug therapies and surgery interventions in escalating the BCC completely
5.2.2. Route of Administration: Rapid effect provided by parenteral administration leading to its preference for managing severe BCC cases
5.2.3. Clinical Variant: Focused efforts to improve and provide advanced treatments for sclerosing and superficial spreading BCC to manage its aggressive nature
5.2.4. End-Users: Government support for expanding and modernizing hospital and clinic facilities
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Basal Cell Carcinoma Treatment Market, by Type
6.1. Introduction
6.2. Drug Therapy
6.3. Radiation Therapy
6.4. Surgery
7. Basal Cell Carcinoma Treatment Market, by Route of Administration
7.1. Introduction
7.2. Oral
7.3. Parenteral
8. Basal Cell Carcinoma Treatment Market, by Clinical Variant
8.1. Introduction
8.2. Nodular Basal Cell Carcinoma
8.3. Pigmented Basal Cell Carcinoma
8.4. Sclerosing Basal Cell Carcinoma
8.5. Superficial Spreading Basal Cell Carcinoma
9. Basal Cell Carcinoma Treatment Market, by End-Users
9.1. Introduction
9.2. Homecare
9.3. Hospitals & Clinics
9.4. Specialty Centres
10. Americas Basal Cell Carcinoma Treatment Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Basal Cell Carcinoma Treatment Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Basal Cell Carcinoma Treatment Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Elekta Unveils Evo, a Groundbreaking Adaptive CT-Linac for Enhanced Cancer Treatment
13.3.2. Medicus Pharma Ltd. Advances Basal Cell Carcinoma Treatment Through Strategic Acquisitions and Enhanced Regulatory Strategies
13.3.3. Innovative Advances in Non-Invasive Basal Cell Carcinoma Treatment by Medicus Pharma Ltd., Update on Regulatory Development and Clinical Studies
13.3.4. Groundbreaking FDA-Cleared Device Enhances Early Detection of Skin Cancer in Primary Care Settings
13.3.5. Final Enrollment and Dosing in Phase 2 Trial of a Non-Surgical Treatment VP-315 for Basal Cell Carcinoma
13.3.6. Strategic Collaboration Between Medison Pharma and Regeneron to Enhance Global Access to Libtayo for Cancer Treatment
13.3.7. Strategic Collaboration between AbbVie and Umoja Biopharma to Advance Oncology Treatment with Innovative Chimeric Antigen Receptor (CAR) T-cell Therapies
13.3.8. Innovative Phase 2 Clinical Study by Medicus Pharma Targets Non-Invasive Treatment for Basal Cell Carcinoma
13.3.9. Bristol Myers Squibb Enhances Oncology Portfolio Through Strategic Acquisitions
13.3.10. EU Approval of Libtayo for Advanced Lung Cancer Broadens Treatment Horizons
13.4. Strategy Analysis & Recommendation
13.4.1. Bausch Health Companies Inc.
13.4.2. Bristol-Myers Squibb Company
13.4.3. Regeneron Pharmaceuticals, Inc.
13.4.4. F. Hoffmann-La Roche AG
13.4.5. Sun Pharmaceutical Industries Ltd.
14. Competitive Portfolio
14.1. Key Company Profiles
14.2. Key Product Portfolio
List of Figures
FIGURE 1. BASAL CELL CARCINOMA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. BASAL CELL CARCINOMA TREATMENT MARKET DYNAMICS
FIGURE 7. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2023 VS 2030 (%)
FIGURE 12. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 14. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. BASAL CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 24. BASAL CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BASAL CELL CARCINOMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TOPICAL MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TOPICAL MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY NODULAR BASAL CELL CARCINOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY NODULAR BASAL CELL CARCINOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PIGMENTED BASAL CELL CARCINOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PIGMENTED BASAL CELL CARCINOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SCLEROSING BASAL CELL CARCINOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SCLEROSING BASAL CELL CARCINOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SUPERFICIAL SPREADING BASAL CELL CARCINOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SUPERFICIAL SPREADING BASAL CELL CARCINOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CENTRES, BY REGION, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CENTRES, BY REGION, 2024-2030 (USD MILLION)
TABLE 49. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 50. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 51. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 52. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 53. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 54. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 55. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 56. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 57. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 58. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 59. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 60. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 61. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 62. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 63. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 64. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 65. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 66. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 67. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 68. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 69. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 70. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 71. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 72. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 73. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 74. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 75. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 76. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 77. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 78. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 79. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 80. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 81. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 82. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 83. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 84. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 85. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 86. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 87. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 88. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 89. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 90. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 91. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 92. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 93. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 94. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 95. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 96. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 97. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 98. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 99. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 100. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 101. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 102. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 103. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 104. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 105. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 106. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 107. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 108. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 109. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 110. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 111. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 112. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 114. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 116. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 118. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 120. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 122. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 124. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 125. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 126. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 127. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 128. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 129. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 130. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 131. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 132. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 133. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 134. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 135. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 136. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 137. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 138. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 139. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 140. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 141. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 142. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 143. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 144. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 145. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 146. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 147. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 148. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 149. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 150. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 151. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 152. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 153. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 154. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 155. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 156. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 157. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 158. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 159. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 160. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 161. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 162. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 163. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 164. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 165. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 166. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 167. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 168. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 169. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 170. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 171. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 172. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 173. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 174. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 175. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 176. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 177. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 178. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 179. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 180. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 181. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 182. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 183. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 184. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 185. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 186. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 187. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 188. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 189. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 190. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 191. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 192. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 193. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 194. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 195. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 196. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 197. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 198. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 199. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 200. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 201. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 202. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 203. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 204. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 205. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 206. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 207. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 208. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 209. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 210. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 211. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 212. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 213. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 214. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 215. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 216. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 217. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 218. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 219. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 220. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 221. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 222. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 223. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 224. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 225. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 226. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 227. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 228. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 229. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 230. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 231. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 232. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 233. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 234. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 235. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 236. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 237. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 238. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 239. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 240. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 241. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 242. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 243. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 244. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 257. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 258. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 259. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 260. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 261. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 262. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 263. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 264. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 265. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 266. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 267. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 268. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 269. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 270. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 271. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 272. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 273. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 274. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 275. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 276. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 277. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 278. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 279. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 280. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 281. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 282. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 283. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 284. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 285. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 286. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 287. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 288. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 289. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 290. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 291. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 292. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 293. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 294. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 295. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 296. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 297. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 298. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 299. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 300. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 301. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 302. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 303. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
TABLE 304. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
TABLE 305. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
TABLE 306. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
TABLE 307. ISRAEL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, B

Companies Mentioned

  • AbbVie Inc.
  • Almirall, LLC
  • Amgen Inc.
  • Bausch Health Companies Inc.
  • Biofrontera AG
  • Bristol-Myers Squibb Company
  • Elekta AB
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Galderma S.A.
  • Glenmark Pharmaceuticals Limited
  • LEO Pharma A/S
  • Medicus Pharma Ltd.
  • Medivir AB
  • OncoBeta GmbH
  • Perrigo Company PLC
  • Redx Pharma PLC
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • SkinCure Oncology
  • Sol-Gel Technologies Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages193
PublishedJune 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 6.94 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.87 Billion
Compound Annual Growth Rate7.6%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Basal Cell Carcinoma Treatment Global Market Report 2024 - Product Image

Basal Cell Carcinoma Treatment Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Basal Cell Carcinoma Treatment - Global Strategic Business Report - Product Image

Basal Cell Carcinoma Treatment - Global Strategic Business Report

  • Report
  • 173 Pages
  • Global
From
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Insight, 2024 - Product Image

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Nevoid basal cell carcinoma syndrome (NBCCS) - Pipeline Insight, 2024 - Product Image

Nevoid basal cell carcinoma syndrome (NBCCS) - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From
Global Basal Cell Carcinoma Treatment Market Analysis & Forecast to 2024-2034 - Product Image

Global Basal Cell Carcinoma Treatment Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From

About the Market

Basal Cell Carcinoma (BCC) is a type of skin cancer that is caused by exposure to ultraviolet radiation from the sun or tanning beds. BCC is the most common type of skin cancer, and is usually found on areas of the body that are exposed to the sun, such as the face, neck, and arms. Treatment for BCC typically involves topical medications, surgery, radiation therapy, or a combination of these treatments. The BCC drug market is composed of a variety of medications used to treat the disease. These medications include topical creams, gels, and ointments, as well as oral medications. Topical medications are typically used to treat superficial BCC, while oral medications are used to treat more advanced cases. Radiation therapy is also used to treat BCC, and is often used in combination with other treatments. The BCC drug market is highly competitive, with a number of companies offering products for the treatment of BCC. Some of the major players in the market include Novartis, Pfizer, Merck, and GlaxoSmithKline. Other companies in the market include Allergan, Galderma, and Sun Pharmaceuticals. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.